Advancing therapeutics with rigor and quality
Welcome to Masinova, a drug development company committed to rigor-led therapeutic R&D using Quality-by-Design principles. We focus on reproducibility, safety, and efficient translation from discovery to preclinical milestones. Explore our science and join us in advancing the future of medicine.
Our approach
Masinova is a rigor-led and Quality-by-Design driven therapeutic R&D. We build reproducible data packages, integrate safety early, and advance programs from discovery through preclinical and IND-enabling milestones toward Phase I.
Therapeutic areas
We focus on developing innovative therapies in several key therapeutic areas. Our research aims to address unmet medical needs and improve patient outcomes through cutting-edge scientific advancements.
Oncology
Developing targeted therapies and innovative treatments to combat various forms of cancer.
Neurology
Advancing research in neurodegenerative diseases to improve patient care and outcomes.
Genetic disorders
Pioneering genetic research to address and treat various inherited genetic disorders.
Immunology
Developing therapies to modulate the immune system and treat infectious and autoimmune diseases.
About masinova
Masinova is a drug development company dedicated to rigor-led therapeutic R&D with Quality-by-Design principles. Our focus on reproducibility, safety, and efficient translation from discovery to preclinical milestones sets us apart. We are committed to advancing the future of medicine through innovation and quality.
Pioneering drug development
Masinova applies Quality-by-Design to de-risk drug development. By prioritizing reproducibility, early safety integration, and disciplined translation, we aim to deliver therapies that can move efficiently from concept to clinical evaluation.
